NRG-GI008

Open to Accrual

Return to Protocol Table

Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

Principal Investigator

Arvind Dasari, MD,

Co-Principal Investigator(s)

Christopher Lieu, MD,

Status

Open to Accrual

Date Opened To Accrual

March 10 2022

Disease Site

Gastrointestinal [GI]

Colorectal

Phase

II/III

Developmental Therapeutics

Primary Objective

This Phase II/III trial will evaluate what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Patient Population

Men or women with Stage IIIAor Stage IIIB (T1-3, N1/N1c) resected colon cancer or ctDNA +ve Stage II orStage IIIC resected colon cancer, R0 resection, and pMMR/MSS.

Target Accrual

1912

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

GI008 Webinar with Natera (July 17, 2024)

Natera Lab Kit Registration

Natera Tissue Return Request Template

Webinar: "Surgical implications of ctDNA: Is this the future for colon cancer?"

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.